Glucose and lipopolysaccharide differentially regulate fibroblast growth factor 21 in healthy male human volunteers - A prospective cross-over trial.
fibroblast growth factor 21
human endotoxin model
lipopolysaccharide
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
12
10
2022
received:
28
07
2022
accepted:
31
10
2022
pubmed:
24
11
2022
medline:
17
12
2022
entrez:
23
11
2022
Statut:
ppublish
Résumé
Fibroblast growth factor 21 (FGF21) affects the regulation of metabolism. Additionally, anti-inflammatory properties are attributed to FGF21, and studies in animals and humans show conflicting results. This study aimed to investigate how FGF21 is affected by glucose and lipopolysaccharide (LPS) in humans. Therefore, FGF21 was measured eight times at different time points within 48 h in this prospective cross-over trial after glucose and LPS on two different study days. The study included ten healthy, non-smoking male subjects aged 18-40. Repeated measures analysis of variance and paired t-test as post hoc analysis were applied. The administration of glucose and LPS resulted in a significant difference in regulating FGF21 (p < 0.001). After glucose administration, FGF21 declined sharply at 360 min, with a subsequent steep increase that exceeded baseline levels. LPS induced a drop in FGF21 after 180 min, while the baseline concentrations were not reached. After 180 min and 24 h, a statistically significant difference was demonstrated after adjusting the Bonferroni-Holm method. So, our results support the hypothesis that glucose and LPS differentially affect the human expression of FGF21 over 48 h.
Identifiants
pubmed: 36415151
doi: 10.1111/jcmm.17614
pmc: PMC9753437
doi:
Substances chimiques
fibroblast growth factor 21
0
Fibroblast Growth Factors
62031-54-3
Glucose
IY9XDZ35W2
Lipopolysaccharides
0
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5998-6005Informations de copyright
© 2022 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Références
Int Immunopharmacol. 2021 Jul;96:107634
pubmed: 33872851
Infect Immun. 2020 Feb 20;88(3):
pubmed: 31843964
Endocr Connect. 2013 Sep 17;2(3):146-53
pubmed: 23999826
PLoS One. 2016 Nov 10;11(11):e0164351
pubmed: 27832059
Trends Endocrinol Metab. 2019 Aug;30(8):491-504
pubmed: 31248786
J Clin Endocrinol Metab. 2012 Jul;97(7):E1224-8
pubmed: 22539584
Cardiovasc Res. 2015 Apr 1;106(1):19-31
pubmed: 25538153
Cell Metab. 2017 Apr 4;25(4):935-944.e4
pubmed: 28380381
Diabetes. 2010 Nov;59(11):2781-9
pubmed: 20682689
Heart Fail Rev. 2019 Nov;24(6):1005-1017
pubmed: 31175491
Endocrinology. 2012 Jun;153(6):2689-700
pubmed: 22474187
Endocr Connect. 2017 Jan;6(1):39-43
pubmed: 28069899
Chem Biol Drug Des. 2012 Apr;79(4):398-410
pubmed: 22248288
Cell Metab. 2016 Feb 9;23(2):335-43
pubmed: 26724858
Endocrinology. 2009 Sep;150(9):4084-93
pubmed: 19470704
J Cardiovasc Transl Res. 2021 Oct;14(5):941-947
pubmed: 33751402
Immune Netw. 2013 Aug;13(4):123-32
pubmed: 24009539
FEBS Lett. 2008 May 28;582(12):1725-30
pubmed: 18460341
Can J Physiol Pharmacol. 2014 Nov;92(11):927-35
pubmed: 25313624
Endocrine. 2015 May;49(1):119-29
pubmed: 25306889
Clin Endocrinol (Oxf). 2009 Sep;71(3):369-75
pubmed: 19702724
J Cell Mol Med. 2022 Dec;26(24):5998-6005
pubmed: 36415151
Proc Natl Acad Sci U S A. 2007 May 1;104(18):7432-7
pubmed: 17452648
Mol Metab. 2014 Oct 08;4(1):51-7
pubmed: 25685689
Diabetes Care. 2011 Sep;34(9):2113-5
pubmed: 21750278
FEBS Lett. 2009 Jan 5;583(1):19-24
pubmed: 19059246
FASEB J. 2001 Sep;15(11):1996-2006
pubmed: 11532980
Physiol Res. 2011;60(4):627-36
pubmed: 21574752
Horm Mol Biol Clin Investig. 2016 Jun 10;30(1):
pubmed: 27285327
Endocr Metab Immune Disord Drug Targets. 2015;15(3):196-205
pubmed: 25772174
Nat Metab. 2021 Mar;3(3):309-317
pubmed: 33758421
Endocrinology. 2004 Jun;145(6):2594-603
pubmed: 14976145
Mol Metab. 2016 Nov 23;6(1):14-21
pubmed: 28123933
Int Immunopharmacol. 2016 Sep;38:144-52
pubmed: 27276443
Am J Transl Res. 2018 Sep 15;10(9):2958-2966
pubmed: 30323882
Int J Obes (Lond). 2015 Jan;39(1):121-9
pubmed: 24813368
Genes Dev. 2021 Jan 1;35(1-2):133-146
pubmed: 33334822
Biotech Histochem. 2022 Jan;97(1):44-52
pubmed: 33663305
Clin Pharmacol Ther. 2014 Oct;96(4):418-22
pubmed: 25236665
ESC Heart Fail. 2019 Oct;6(5):983-991
pubmed: 31429530
Acta Biochim Biophys Sin (Shanghai). 2014 Dec;46(12):1041-8
pubmed: 25355486
PLoS One. 2014 Apr 14;9(4):e94996
pubmed: 24733293
Ir J Med Sci. 2017 Aug;186(3):785-794
pubmed: 28181108
Annu Rev Physiol. 2016;78:223-41
pubmed: 26654352
Diabetes. 2008 May;57(5):1246-53
pubmed: 18252893
Cell Metab. 2016 Feb 9;23(2):344-9
pubmed: 26724861
Cell Rep. 2017 Oct 10;21(2):403-416
pubmed: 29020627
FEBS Lett. 2009 Sep 3;583(17):2882-6
pubmed: 19660458
Eur Respir J. 2019 Feb 28;53(2):
pubmed: 30578395
Mol Metab. 2016 Nov 16;6(1):22-29
pubmed: 28123934
Cytokine. 2018 Nov;111:428-433
pubmed: 29861384
Mol Metab. 2017 Mar 27;6(6):602-610
pubmed: 28580290
PLoS One. 2016 Feb 12;11(2):e0148252
pubmed: 26872145
Circulation. 2015 May 26;131(21):1861-71
pubmed: 25794851
Diabetes Care. 2009 Aug;32(8):1542-6
pubmed: 19487637
Sci Rep. 2020 Nov 11;10(1):19521
pubmed: 33177640
Curr Med Chem. 2008;15(17):1697-705
pubmed: 18673219
J Biol Chem. 2016 Jul 15;291(29):15378-87
pubmed: 27226639
Endocrinology. 2002 May;143(5):1741-7
pubmed: 11956156
Biochem Biophys Res Commun. 2012 Sep 7;425(4):866-72
pubmed: 22898050